By Manufacturer Type

Biosimilar / Authorized Generic Market Analysis

Cross-industry research covering Biosimilar / Authorized Generic across 1 market reportspanning Pharmaceuticals & Medical Devices — Ophthalmic Surgery.

1 Reports
1 Industries

Reports Covering Biosimilar / Authorized Generic

Oculoplastic Surgery Market to Reach USD 8.4 Billion by 2033 at 7.2% CAGR

Pharmaceuticals & Medical Devices — Ophthalmic Surgery·Market: USD 4.8 Billion (2025)·CAGR: 7.2%

Currently negligible in TED biologics but will enter after Tepezza's exclusivity window; botulinum toxin biosimilar competition is already active, with FDA-approved interchangeable formulations from IncobotulinumtoxinA (Xeomin) and abobotulinumtoxinA (Dysport) eroding Allergan's dominant share in periocular neuromodulator indications.

8%

Market Share

14.2%

Segment CAGR

Explore More Segments

Browse all market segments across our research coverage.

View all segments